In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Previous cardiomyopathy in cardiogenic shock

Session Poster Session 1

Speaker Helder Santos

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : H Santos (Barreiro,PT), J Fernandes (Porto,PT), T Vieira (Porto,PT), R Pinto (Porto,PT), T Filipa (Porto,PT), AR Ferreira (Porto,PT), M Rios (Porto,PT), T Honrado (Porto,PT)

H Santos1 , J Fernandes2 , T Vieira2 , R Pinto3 , T Filipa3 , AR Ferreira2 , M Rios2 , T Honrado2 , 1Hospital N.S. Rosario, Cardiology - Barreiro - Portugal , 2Sao Joao Hospital, Intensive Care - Porto - Portugal , 3Sao Joao Hospital, Cardiology - Porto - Portugal ,


Background: Cardiogenic shock (CS) remains the major cause of death in acute coronary syndrome, and the presence of a previous cardiac dysfunction can influence the outcome.
Purpose: Evaluate the impact of previous cardiomyopathy in CS and the predictors of mortality in CS patients.
Methods: Single-centre retrospective study, engaging patients hospitalized for CS between 1/04/2016-31/10/2018. Multiple linear regression was performed to assess predictors of mortality at admission in CS patients. Then, patients were divided in two groups: A - previous cardiomyopathy in CS, and B - CS without a history of cardiomyopathy. Chi-square, Fisher and T-student tests were used to compare categorical and continuous variables.
Results: 214 patients were included, mean age 62.36±13.92 years, with 78.5% males. Arterial hypertension (AH) (53.3%), dyslipidaemia (DL) (46.7%) and smokers (31.6%) are the most frequent comorbidities. Beta blockers (BB) (31.6%), Angiotensin-Converting-Enzyme inhibitor (ACEI) (40.9%) and platelet antiaggregant (PA) (30.8%) are frequent medications before the CS occurrence. Multiple linear regression revealed age, AH, and ACEI as predictors of CS mortality with an R2a of 0.096 – Table 1. In the group A (50 patients) the most prevalent aetiologies were ischemic (50%), valvular (24%) and alcoholic (12%). The groups were similar regarding gender, AH, DL, diabetes, obesity, values of cardiac troponins, creatinine and platelet count, arterial pressure and arrhythmias at admission and mortality rates. Group A were older (66.34±15.49 vs 61.15±13.22 years, p=0.021), use more cardiovascular medication, BB (81 vs 15.7%, p?0.001), ACEI (60 vs 34.8%, p=0.002), spironolactone (24 vs 4.4%, p?0.001), furosemide (40 vs 11.9%, p?0.001) and PA (53.1 vs 23.9%, p?0.001); at admission presented lower values of haemoglobin (12.39±2.44 vs 13.46±2.24, p=0.008) and leukocytes (13.02±10.27 vs 15.4±7.7, p=0.043). Group B had more angiography performed (84.8 vs 64%, p=0.001), and less time until the angiography (3±3 vs 3.5±2.88 hours, p=0.001) and higher left ventricular ejection fraction (35.64±13.59 vs 28.22±14.07, p=0.02). Linear regression confirmed that previous cardiomyopathy did not influence the mortality rates in CS patients, p=0.612.
Conclusions: Age and AH are the major predictors of mortality in CS and the use of ACEI seems have a protective effect.

Independent Variables

β (95% CI)

P value


0.205 (0.002 - 0.013)


Arterial Hypertension

0.230 (0.067 - 0.390)



-0.252 (-0.409 - -0.100)


Multiple linear regression models for prediction of mortality in cardiogenic shock.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are